Sherlock Biosciences raises $80M Series B for at-home diagnostics

Sherlock Biosciences announced today that it raised $80 million in a Series B financing round to support its next-generation diagnostics.

Novalis LifeSciences led the round, which included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. The new investors joined Northpond Ventures, Good Ventures and other existing investors, bringing Sherlock’s total funding to $111 million to date.

Boston-based Sherlock develops a CRISPR-based method for detecting and quantifying genetic sequences and Inspectr, a synthetic biology-based, instrument-free molecular diagnostic platform. It was included in MassDevice’s 2020 list of medical device startups you need to know.

Sherlock said in a news release that the latest funding will drive the development of products and partnerships enabled by the company’s proprietary platform that can operate at ambient temperature without complex instrumentation, opening up a range…

Read more
  • 0

Sherlock Biosciences names new CEO

Sherlock Biosciences announced today it appointed Bryan Dechairo as its president and CEO and he will join the company’s board.

Dechairo will succeed co-founder Rahul Dhanda, who will continue to serve as a board member until the end of 2021, after which he will assume the role of strategic adviser in 2022.

He joins Cambridge, Mass.-based Sherlock Biosciences after most recently holding the position of executive VP of clinical development at Myriad Genetics. He was chief medical officer, chief scientific officer and senior VP of R&D at Assurex Health, which Myriad acquired in 2016.

Before Assurex Health, Dechairo held leadership positions at Medco Health Solutions, Pfizer and other diagnostic and therapeutics companies, according to a news release.

“I’m thrilled to be joining Sherlock at such a pivotal moment for the company,” Dechairo said in the release. “The past year’s successes are a remarkable testament to the commitment of this te…

Read more
  • 0

20 medical device startups you need to know

The medtech industry isn’t immune from COVID-19 troubles, but exciting innovation continues. These 20 medical device startups have grabbed our attention.

Tom Salemi, DeviceTalks Editorial Director and Sean Whooley, Assistant Editor

A number of medical device startups continue to make waves across the space, with new technologies and eye-watering fundraising rounds highlighting some exciting prospects.

From treating children with congenital heart disease to therapy that alleviates the effects of traumatic nightmares — and with plenty more innovations between — there is no shortage of intriguing medical devices and therapies coming up through the ranks.

“Even in the face of the COVID-19 pandemic, we continue to see tremendous energy in the medtech innovation ecosystem,” said Paul Grand, CEO of MedTech Innovator. “We are noticing a strong trend of minimally invasive medical devices that improve patient outcomes and require less time spent in th…

Read more
  • 0

20 medical device startups you need to know

The medtech industry isn’t immune from COVID-19 troubles, but exciting innovation continues. These 20 medical device startups have grabbed our attention.

Tom Salemi, DeviceTalks Editorial Director and Sean Whooley, Assistant Editor

A number of medical device startups continue to make waves across the space, with new technologies and eye-watering fundraising rounds highlighting some exciting prospects.

From treating children with congenital heart disease to therapy that alleviates the effects of traumatic nightmares — and with plenty more innovations between — there is no shortage of intriguing medical devices and therapies coming up through the ranks.

“Even in the face of the COVID-19 pandemic, we continue to see tremendous energy in the medtech innovation ecosystem,” said Paul Grand, CEO of MedTech Innovator. “We are noticing a strong trend of minimally invasive medical devices that improve patient outcomes and require less time spent in th…

Read more
  • 0

Sherlock Biosciences announces manufacturing partnership for CRISPR-based COVID-19 test

Sherlock Biosciences announced today that it will collaborate with Integrated DNA Technologies (IDT) to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for COVID-19 detection.

Officials at Cambridge, Mass.–based Sherlock Biosciences think the company’s CRISPR-based diagnostic test, which recently received an FDA emergency use authorization, will increase testing capacity and decreasing time to result amid the coronavirus pandemic.

Get the full story on our sister site Pharmaceutical Processing World. 

Read more
  • 0